Goldman Sachs
RPRX icon

Goldman Sachs’s Royalty Pharma RPRX Stock Holding History

Goldman Sachs’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,000
Closed -$1.2M – 6931
2026
Q1 		$1.2M Hold
25,000
– – ﹤0.01% 4965
2025
Q4 		$966K Buy
+25,000
New +$953K ﹤0.01% 5169
2022
Q2 		– Sell
-100,000
Closed -$3.9M – 6670
2022
Q1 		$3.9M Buy
+100,000
New +$3.93M ﹤0.01% 3588
2021
Q3 		– Sell
-68,000
Closed -$2.79M – 6474
2021
Q2 		$2.79M Buy
+68,000
New +$2.89M ﹤0.01% 3908

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's RPRX Position: Q2 2026 in Review

Goldman Sachs reduced its Royalty Pharma (RPRX) stake by 4.2% in Q2 2026, selling an estimated $5.53M and leaving 2,416,331 shares worth $135M. The position accounts for 0.01% of the portfolio, ranked #995.

Goldman Sachs first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Goldman Sachs held 2,416,331 shares of Royalty Pharma worth $135M as of Q2 2026.
  • Goldman Sachs sold 106,215 Royalty Pharma shares in Q2 2026, an estimated $5.53M.
  • Royalty Pharma made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #995 holding.
  • Goldman Sachs first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.